双难治性多发性骨髓瘤基因组与转录组景观整合分析
该研究对42例对蛋白酶体抑制剂(PI)和免疫调节剂(IMiD)均难治的多发性骨髓瘤患者进行全外显子组测序(40例)和RNA测序(27例),发现TP53通路失活最常见(45%),IMiD耐药相关基因点突变罕见且均为亚克隆,难治患者具有烷化剂暴露相关突变特征,仅amp(1q)预测生存。
要点
- TP53通路失活见于45%的双难治患者,为最常见事件。
- IMiD和PI靶基因突变不是骨髓瘤耐药的主要模式。
- 仅amp(1q)预测双难治患者生存。
核心结论
- IMiD和PI靶基因突变不是骨髓瘤耐药的首选模式。
- 大肿瘤群体的化疗耐药可能通过亚克隆的分化但趋同进化获得,患者间及患者内均高度可变。
研究设计与样本
- 研究纳入42例对PI和IMiD均难治的多发性骨髓瘤患者。
- 对40例患者行全外显子组测序,对27例行RNA测序。
主要发现
- 与诊断时相比,难治患者携带更多突变和更多亚克隆突变。
- 突变景观与已发表的诊断时样本研究不同。
- TP53通路在45%的患者中失活,为最常见事件。
- IMiD耐药相关基因点突变罕见且均为亚克隆。
- 难治患者具有与烷化剂暴露相关的突变特征。
关键数值与推荐
- TP53通路失活频率为45%。
- 高危特征见于65%的患者。
- 仅amp(1q)预测生存。
临床怎么用
- 对双难治患者应关注TP53通路状态和amp(1q)以评估高危。
- MCL1过表达提示其可作为实验性治疗的新靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In multiple myeloma, novel treatments with proteasome inhibitors (PIs) and immunomodulatory agents (IMiDs) have prolonged survival but the disease remains incurable. At relapse, next-generation sequencing has shown occasional mutations of drug targets but has failed to identify unifying features that underlie chemotherapy resistance. We studied 42 patients refractory to both PIs and IMiDs. Whole-exome sequencing was performed in 40 patients, and RNA sequencing (RNA-seq) was performed in 27. We found more mutations than were reported at diagnosis and more subclonal mutations, which implies ongoing evolution of the genome of myeloma cells during treatment. The mutational landscape was different from that described in published studies on samples taken at diagnosis. The TP53 pathway was the most frequently inactivated (in 45% of patients). Conversely, point mutations of genes associated with resistance to IMiDs were rare and were always subclonal. Refractory patients were uniquely characterized by having a mutational signature linked to exposure to alkylating agents, whose role in chemotherapy resistance and disease progression remains to be elucidated. RNA-seq analysis showed that treatment or mutations had no influence on clustering, which was instead influenced by karyotypic events. We describe a cluster with both amp(1q) and del(13) characterized by CCND2 upregulation and also overexpression of MCL1, which represents a novel target for experimental treatments. Overall, high-risk features were found in 65% of patients. However, only amp(1q) predicted survival. Gene mutations of IMiD and PI targets are not a preferred mode of drug resistance in myeloma. Chemotherapy resistance of the bulk tumor population is likely attained through differential, yet converging evolution of subclones that are overall variable from patient to patient and within the same patient.
引用
- Ziccheddu B, Biancon G, Bagnoli F, et al. Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. Blood Adv. 2020. PMID: 32126144. doi:10.1182/bloodadvances.2019000779
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。